<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617864</url>
  </required_header>
  <id_info>
    <org_study_id>0707002880</org_study_id>
    <nct_id>NCT00617864</nct_id>
  </id_info>
  <brief_title>The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome</brief_title>
  <official_title>The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study was designed to look at the effect of human albumin transfusion on&#xD;
      circulating levels of Vascular Endothelial Derived Growth Factor (VEGF), a protein that is&#xD;
      believed to be responsible for the syndrome of ovarian hyperstimulation. Patients have been&#xD;
      asked to participate because they are identified as at risk for the Ovarian Hyperstimulation&#xD;
      Syndrome (OHSS), a potentially serious complication of in vitro fertilization. It has been&#xD;
      established that the onset of OHSS may be preventable by the infusion of albumin at the time&#xD;
      of egg retrieval; however, we do not know by what mechanism albumin works. As we know the&#xD;
      pathogenesis of OHSS is related to VEGF released from the ovaries, we believe human albumin&#xD;
      may serve to &quot;bind up&quot; this VEGF and prevent it from causing its harmful effects. The purpose&#xD;
      of this study is to evaluate the effect of albumin infusion on blood and urine VEGF levels in&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The&#xD;
    study was withdrawn and never started.&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum VEGF levels</measure>
    <time_frame>Time surrounding egg retrieval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine VEGF levels</measure>
    <time_frame>Time surrounding egg retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>Time surrounding egg retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group will receive infusion of human albumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group will receive infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Albumin Infusion</intervention_name>
    <description>Group will receive single infusion of albumin at the time of oocyte retrieval.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Infusion</intervention_name>
    <description>Group will receive single infusion of saline at the time of oocyte retrieval.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infertile patients undergoing in vitro fertilization with or without ICSI&#xD;
&#xD;
          -  Estradiol &gt; 3000 pg/mL at the time of hCG administration&#xD;
&#xD;
          -  &gt;/= 20 follicles seen during ultrasound monitoring&#xD;
&#xD;
          -  Patients with polycystic ovarian syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with only one ovary&#xD;
&#xD;
          -  Patients with medical contraindication to human albumin (hypersensitivity,&#xD;
             hypervolemia, cardiac insufficiency, hypertension, esophageal varices, pulmonary&#xD;
             edema, severe anemia, renal failure)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquale Patrizio, MD, MBE, HCLD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Fertility Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>February 20, 2012</last_update_submitted>
  <last_update_submitted_qc>February 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

